$TVRD

Tvardi Therapeutics, Inc.

Tvardi Therapeutics is a clinical-stage biopharmaceutical company based in Sugar Land, Texas. It develops oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) for patients with inflammatory and proliferative diseases. Tvardi’s pipeline includes TTI-101, a direct STAT3 inhibitor in Phase 1b/2 clinical development for hepatocellular carcinoma, and TTI-109, a phosphate prodrug designed to convert to TTI-101 in the bloodstream. TTI-109 is in a Phase 1 trial in healthy volunteers evaluating safety, tolerability, pharmacokinetics and bioequivalence to TTI-101. Tvardi has also studied TTI-101 in idiopathic pulmonary fibrosis.

1
1
3

No SEC Form 4 filings for $TVRD in the last 30 days.

See all $TVRD insider activity →
Low

Raymond James reiterates Tvardi Therapeutics stock rating on HCC data

Raymond James reiterated an Outperform rating and $10.00 price target for Tvardi Therapeutics (TVRD) after Q3 2026 earnings, citing encouraging data for TTI-101 in HCC and TTI-109's tolerability. The stock is down 73% YTD but appears undervalued, with upward earnings revisions. The HCC readout is delayed to Q1 2027. Other analysts also initiated coverage with buy ratings and price targets ranging from $8.00 to $14.00.

Tvardi Therapeutics Reports Q3 2026 Net Loss of $6.1 Million

Tvardi Therapeutics reported a Q3 2026 net loss of $6.1M, up from $5.5M a year earlier. R&D expenses rose to $4.5M, while G&A expenses fell to $1.9M. The company had $22.3M in cash and expects funds to last into Q3 2027. Tvardi is preparing to advance TTI-109 into clinical trials for ulcerative colitis and expects Phase 1b/2 REVERT LIVER CANCER study results in early Q1 2027.

Tvardi Therapeutics Announces Third Quarter 2026 Results and Provides Business Update

Tvardi Therapeutics, Inc. (TVRD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ​ ​ Tvardi Therapeutics Announces Third Quarter 2026 Results and Provides Business Update HOUSTON, TX – November 13, 2026 – Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of

TVRD sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 5 news stories mentioning TVRD (Tvardi Therapeutics, Inc.). Coverage has skewed bearish: 1 bullish, 1 neutral, and 3 bearish.

Recent TVRD coverage spans earnings, financial news and technology.

What's driving TVRD

  • Analyst upgrade may lift the stock modestly.

    investing.com · Nov 16, 2026

  • The loss and modest cash runway suggest short‑term pressure on the stock, but the advancement of TTI‑109 and upcoming trial data could provide upside.

    tradingview.com · Nov 13, 2026

  • The earnings miss and modest cash runway may weigh on the stock, but advancing clinical programs could provide upside if data are positive.

    SEC EDGAR 8-K · Nov 13, 2026

  • Analyst coverage may provide modest upside if the company secures needed financing; downside risk remains due to going-concern concerns.

    investing.com · Oct 20, 2026

  • Positive early pharmacodynamic and tolerability signals for TTI-109 in healthy volunteers, with UC selected as the initial indication and a defined next catalyst (Aug 19 webinar).

    SEC EDGAR 8-K · Aug 14, 2026

AlphAI scores every news story that mentions TVRD with an AI model for sentiment and relevance, and aggregates insider trades from Tvardi Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $TVRD

Score

Raymond James reiterates Tvardi Therapeutics stock rating on HCC data

Raymond James reiterated an Outperform rating and $10.00 price target for Tvardi Therapeutics (TVRD) after Q3 2026 earnings, citing encouraging data for TTI-101 in HCC and TTI-109's tolerability. The stock is down 73% YTD but appears undervalued, with upward earnings revisions. The HCC readout is delayed to Q1 2027. Other analysts also initiated coverage with buy ratings and price targets ranging from $8.00 to $14.00.

Tvardi Therapeutics Reports Q3 2026 Net Loss of $6.1 Million

Tvardi Therapeutics reported a Q3 2026 net loss of $6.1M, up from $5.5M a year earlier. R&D expenses rose to $4.5M, while G&A expenses fell to $1.9M. The company had $22.3M in cash and expects funds to last into Q3 2027. Tvardi is preparing to advance TTI-109 into clinical trials for ulcerative colitis and expects Phase 1b/2 REVERT LIVER CANCER study results in early Q1 2027.

$TVRDMedEarnings

Tvardi Therapeutics Announces Third Quarter 2026 Results and Provides Business Update

Tvardi Therapeutics, Inc. (TVRD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ​ ​ Tvardi Therapeutics Announces Third Quarter 2026 Results and Provides Business Update HOUSTON, TX – November 13, 2026 – Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of

Chardan initiates Tvardi Therapeutics stock with buy on STAT3 platform

Chardan initiated coverage on Tvardi Therapeutics (NASDAQ:TVRD) with a buy rating and $8.00 price target, contingent on raising $35-40M for ulcerative colitis trials. The stock trades at $0.97, down 84% YoY, with a $15M market cap. Chardan estimates $1.6B peak sales at 20% success probability. H.C. Wainwright and Lucid Capital also rated TVRD Buy with $9.00 and $14.00 targets, respectively, citing positive clinical data.

$TVRDMedEarnings

Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update

Tvardi Therapeutics, Inc. (TVRD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update Reported topline healthy volunteer results for next-generation STAT3 inhibitor TTI-109, confirming the prodrug design, improved tolerability and reductions in disease-relevant immu

Tvardi Therapeutics (Nasdaq: TVRD) Soars on Positive Phase 1 Results for Next-Gen STAT3 Inhibitor TTI-109

Tvardi Therapeutics (NASDAQ: TVRD) reported Phase 1 results for its oral STAT3 inhibitor TTI-109. The company said TTI-109 rapidly converts to TTI-101, shows dose-proportional pharmacokinetics with exposures above the STAT3 IC50, and reduced STAT3-driven immune cell populations by up to 60% in exploratory analyses. It also cited shorter diarrhea duration vs TTI-101. TVRD shares rose sharply on the news.

$TVRDMedAI 8/10

Why Is Tvardi Therapeutics Stock Gaining Tuesday? - Tvardi Therapeutics (NASDAQ:TVRD)

Tvardi Therapeutics (NASDAQ:TVRD) reported Phase 1 results for TTI-109, a STAT3 inhibitor prodrug. The company said TTI-109 converted to TTI-101 within two hours, showed dose-proportional pharmacokinetics and target engagement, and had diarrhea events comparable to placebo (0.46 vs 3.35 days vs near-equivalent TTI-101). Shares rose ~49.75% to $3.01; plans to advance into dermatologic and gastrointestinal indications pending IND clearance and funding.

Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement

Tvardi Therapeutics (NASDAQ: TVRD) reported Phase 1 results for TTI-109, a STAT3 inhibitor prodrug of TTI-101. The company said TTI-109 rapidly converts to TTI-101, shows dose-proportional PK with exposures above the STAT3 IC50, and reduced STAT3-driven immune cell populations by up to 60%. It plans to advance TTI-109 into dermatologic and GI diseases pending IND clearance and funding; webcast July 7, 8:30am ET.

Top Biotech Gainers: UPC Expands Patent Portfolio, All Eyes On SLS, What's Behind The QDEL Rumor?

Biotech gainers highlighted: Universe Pharma (UPC) surged 311% after agreeing to buy Best Praise International for $10.75M in shares to expand its China patent portfolio; Decoy Therapeutics (DCOY) rose 74% on a PIPE up to $21M; QuidelOrtho (QDEL) gained 32% on reports it may sell its point-of-care unit for about $1.5B; SELLAS (SLS) jumped 25% ahead of AML trial readouts.

Related tickers